<DOC>
	<DOC>NCT01302080</DOC>
	<brief_summary>To evaluate the long-term impact of treatment with sertraline on aspects of cognitive, emotional and physical development and pubertal maturation in pediatric subjects ages 6 to 16 years (inclusive) with a diagnosis of anxiety disorder, depressive disorder or obsessive compulsive disorder.</brief_summary>
	<brief_title>Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)</brief_title>
	<detailed_description>Purposive sample: patients are not randomly selected, that is, he or she must meet certain inclusion criteria in order to qualify as a potential study participant.</detailed_description>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<criteria>Children age 6 to 16 (inclusive) with anxiety, depression, or obsessivecompulsive disorder, receiving treatment in outpatient setting, and who are prescribed a new prescription for sertraline to treat one of the above studyqualifying disorders or beginning psychotherapy for same. Psychotic at study entry Diagnosis of bipolar disorder Diagnosis of schizoaffective or schizophrenia Anorexia Bulimia or eating disorder not otherwise specified (NOS) Autism Pervasive developmental disorder High risk of suicide within 2 weeks of initiating study treatment Significant mental retardation</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>prospective</keyword>
	<keyword>cohort</keyword>
	<keyword>sertraline</keyword>
	<keyword>long-term impact</keyword>
	<keyword>cognition</keyword>
	<keyword>emotional and physical development</keyword>
	<keyword>pubertal maturation</keyword>
</DOC>